Logo image of AMRN

AMARIN CORP PLC -ADR (AMRN) Stock Price, Quote, News and Overview

NASDAQ:AMRN - Nasdaq - US0231112063 - ADR - Currency: USD

0.594  +0 (+0.49%)

After market: 0.59 0 (-0.67%)

AMRN Quote, Performance and Key Statistics

AMARIN CORP PLC -ADR

NASDAQ:AMRN (2/20/2025, 8:00:00 PM)

After market: 0.59 0 (-0.67%)

0.594

+0 (+0.49%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High1.36
52 Week Low0.43
Market Cap244.33M
Shares411.34M
Float404.57M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO04-01 1993-04-01


AMRN short term performance overview.The bars show the price performance of AMRN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5

AMRN long term performance overview.The bars show the price performance of AMRN in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of AMRN is 0.594 USD. In the past month the price increased by 8.63%. In the past year, price decreased by -50.08%.

AMARIN CORP PLC -ADR / AMRN Daily stock chart

AMRN Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.85 354.98B
AMGN AMGEN INC 15.03 159.99B
GILD GILEAD SCIENCES INC 23.87 137.10B
VRTX VERTEX PHARMACEUTICALS INC 1656.31 123.40B
REGN REGENERON PHARMACEUTICALS 15.25 76.09B
ARGX ARGENX SE - ADR N/A 39.34B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.37B
BNTX BIONTECH SE-ADR N/A 28.26B
ONC BEIGENE LTD-ADR N/A 26.06B
NTRA NATERA INC N/A 22.20B
BIIB BIOGEN INC 8.32 19.98B
SMMT SUMMIT THERAPEUTICS INC N/A 17.01B

About AMRN

Company Profile

AMRN logo image Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The firm operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Company Info

AMARIN CORP PLC -ADR

First Floor, Block 3, The Oval,, Shelbourne Road, Ballsbridge

DUBLIN Dublin 2 IE

CEO: John F. Thero

Employees: 275

Company Website: https://amarincorp.com/

Investor Relations: https://amarincorp.com/investor-relations

Phone: 35316699020

AMARIN CORP PLC -ADR / AMRN FAQ

What is the stock price of AMARIN CORP PLC -ADR today?

The current stock price of AMRN is 0.594 USD. The price increased by 0.49% in the last trading session.


What is the ticker symbol for AMARIN CORP PLC -ADR stock?

The exchange symbol of AMARIN CORP PLC -ADR is AMRN and it is listed on the Nasdaq exchange.


On which exchange is AMRN stock listed?

AMRN stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for AMARIN CORP PLC -ADR stock?

8 analysts have analysed AMRN and the average price target is 1.02 USD. This implies a price increase of 71.72% is expected in the next year compared to the current price of 0.594. Check the AMARIN CORP PLC -ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is AMARIN CORP PLC -ADR worth?

AMARIN CORP PLC -ADR (AMRN) has a market capitalization of 244.33M USD. This makes AMRN a Micro Cap stock.


How many employees does AMARIN CORP PLC -ADR have?

AMARIN CORP PLC -ADR (AMRN) currently has 275 employees.


What are the support and resistance levels for AMARIN CORP PLC -ADR (AMRN) stock?

AMARIN CORP PLC -ADR (AMRN) has a support level at 0.54 and a resistance level at 0.6. Check the full technical report for a detailed analysis of AMRN support and resistance levels.


Is AMARIN CORP PLC -ADR (AMRN) expected to grow?

The Revenue of AMARIN CORP PLC -ADR (AMRN) is expected to decline by -31.86% in the next year. Check the estimates tab for more information on the AMRN EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy AMARIN CORP PLC -ADR (AMRN) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does AMARIN CORP PLC -ADR (AMRN) stock pay dividends?

AMRN does not pay a dividend.


What is the Price/Earnings (PE) ratio of AMARIN CORP PLC -ADR (AMRN)?

AMARIN CORP PLC -ADR (AMRN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.09).


What is the Short Interest ratio of AMARIN CORP PLC -ADR (AMRN) stock?

The outstanding short interest for AMARIN CORP PLC -ADR (AMRN) is 4.16% of its float. Check the ownership tab for more information on the AMRN short interest.


AMRN Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to AMRN. When comparing the yearly performance of all stocks, AMRN is a bad performer in the overall market: 86.47% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

AMRN Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to AMRN. While AMRN seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AMRN Financial Highlights

Over the last trailing twelve months AMRN reported a non-GAAP Earnings per Share(EPS) of -0.09. The EPS increased by 30.77% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -5.24%
ROE -7.4%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-20%
Sales Q2Q%-35.97%
EPS 1Y (TTM)30.77%
Revenue 1Y (TTM)-25.26%

AMRN Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 43% to AMRN. The Buy consensus is the average rating of analysts ratings from 8 analysts.

For the next year, analysts expect an EPS growth of -2% and a revenue growth -31.86% for AMRN


Ownership
Inst Owners19.76%
Ins Owners1%
Short Float %4.16%
Short Ratio11.27
Analysts
Analysts42.5
Price Target1.02 (71.72%)
EPS Next Y-2%
Revenue Next Year-31.86%